#None #AI Technology #Okomera #Ocentra

Okomera Launches Ocentra for Automated Organoid Screening

Okomera, an innovative biotech company, has announced the opening of pre-orders for their first commercial product, Ocentra. This cutting-edge system was officially unveiled at major events including the MPS World Summit in Brussels and Vivatech Paris. Ocentra is specifically engineered to optimize the processes involved in organoid-based drug discovery, a field that has gained significant traction in modern biomedical research.

What is Ocentra?

Powered by advanced microfluidic technology, Ocentra is a plug-and-play bioreactor that automates both the formation of organoids and the multiplexed screenings required for drug development. Researchers are empowered to conduct diverse assays using as few as 50 cells per organoid, which makes it an ideal tool for both fresh and frozen biopsies. The system supports a broad range of testing methodologies, including small-molecule assays, biologics, immune co-culture experiments, and CRISPR-based approaches utilizing lentiviruses.

One of the standout features of Ocentra is its seamless integration with Okomera's proprietary analysis software, Okomera AI. This software facilitates the flow of imaging data, ensuring a smooth transition from sample preparation to actionable insights, thus reducing the time and complexity traditionally associated with organoid screening processes.

Revolutionary Impact on Research

In a statement, Sidarth Radjou, the CEO of Okomera, emphasized the game-changing potential of Ocentra: "Ocentra brings simplicity and scalability to complex biology. Researchers can now shorten the journey from sample to actionable data, enabling them to focus more on discovery and less on logistics."

Dr. Pierre Savagner, a prominent researcher at INSERM and the first user of Ocentra, expressed his enthusiasm for the technology. He recalled first seeing the system in 2019 and recognizing its potential for preclinical ex-vivo studies. "Ocentra could make that vision a robust, user-friendly reality," he affirmed.

Opportunities to Interact with Okomera

Okomera's dedicated team will be showcasing Ocentra at VivaTech in Paris, which runs from June 11-14, as well as attending the BIO International Convention in Boston from June 16-19. These events present a prime opportunity for interested parties to explore pre-order options and engage with the experts behind this innovative technology.

For media inquiries or to schedule a direct meeting with Okomera's leadership, interested individuals can contact Sidarth Radjou at their provided email.

About Okomera

Founded with a vision to advance the practices of organoid screening in drug discovery, Okomera specializes in developing intelligent instruments that leverage the power of microfluidics, automation, and artificial intelligence. The advent of Ocentra marks a significant milestone in the company's journey to revolutionize biomedical research.

As the landscape of drug discovery evolves, Ocentra stands at the forefront, ready to empower researchers with more accessible and efficient means to conduct vital experiments. Stay tuned for more updates as Okomera shares further developments and insights from their applications in the field.